Market Overview

Acceleron, Celgene Report New Interim Clinical Data from Phase 2 Trial of Sotatercept in Beta-Thalassemia at ASH

Related XLRN
4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate
Benzinga's Top Upgrades, Downgrades For October 12, 2017

Acceleron Pharma (NASDAQ: XLRN) today announced
that its collaboration partner Celgene (NASDAQ: CELG) reported new interim data at the
55th American Society of Hematology (ASH) Annual Meeting of
sotatercept in patients with beta-thalassemia. Interim data presented
from the ongoing phase 2 trial demonstrate dose dependent increases in
hemoglobin in non-transfusion dependent beta-thalassemia patients.
Beta-thalassemia is a genetic hematologic disorder causing chronic and
life-threatening anemia and serious complications affecting the spleen,
liver and heart.

The data were presented in a poster session by Maria Domenica
Cappellini, M.D., University of Milan,

See full press release

Posted-In: News Guidance Asset Sales Management Global


Related Articles (CELG + XLRN)

View Comments and Join the Discussion!